본문 바로가기

Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q3
피인용
Web of Science 9Scopus 10
FWCI (Scopus)
1.38
JCR IF
JCR 2022 2.9
ISSN
0378-6323

저자

  1. 신준오제1저자Pusan Natl Univ, Dept Dermatol, Yangsan Hosp, Yangsan, South Korea
  2. Shin, Bong SeokChosun Univ Hosp, Dept Dermatol, 365 Pilmun Daero, Gwangju, South Korea
  3. 배경남
  4. 신기혁Pusan Natl Univ, Dept Dermatol, Yangsan Hosp, Yangsan, South Korea
  5. 김훈수Chosun Univ Hosp, Dept Dermatol, 365 Pilmun Daero, Gwangju, South Korea
  6. 고현창Pusan Natl Univ, Dept Dermatol, Yangsan Hosp, Yangsan, South Korea
  7. 김문범Chosun Univ Hosp, Dept Dermatol, 365 Pilmun Daero, Gwangju, South Korea
  8. 김병수교신저자Pusan Natl Univ Hosp, Dept Dermatol, 305 Gudeok Ro, Pusan, South Korea

초록

Background: Switching of biologics in patients has become common in clinical practice. Objectives: This study investigated the reasons for and effectiveness of switching biologic agents during the treatment of psoriasis. Methods: We retrospectively reviewed patients with psoriasis who were treated with biologics at Pusan National University Hospital and Chosun University Hospital from March 2012 to June 2020. We assessed their demographics and treatment characteristics (reasons for switching biologics and efficacy of the first- and second biologic agents). Results: Of the 162 psoriatic patients treated with biologic agents for more than 52 weeks, 35 required a switch to another biologic agent. The reasons for switching biologic agents were inefficacy (n = 30), adverse events (n = 2) and others (n = 3). The mean psoriasis area and severity index (PASI) score was 12.1 at the start of the second biologic and 3.4 at 14–16 weeks later. Patients were more likely to switch to another biologic agent when they exhibited a high initial psoriasis area and severity index score and concomitant psoriatic arthritis. Limitations: As a retrospective study, there were some limitations such as lack of a placebo control group and the time point of 14–16 weeks being somewhat early to judge the effect of the biologics. Conclusions: The most common reason for switching biologic agents in Korea was treatment inefficacy, especially secondary failure. Despite the inefficacy of previous biologic agents, switching to a different agent may be an efficacious approach.

키워드

BiologicspsoriasistreatmentSAFETY

식별자

Scopus EID
2-s2.0-85170365426
WoS UID
001102293200002